IndraLab

Statements

PK/PD inhibits USP30. 1 / 1

| 1

reach

"Additionally, the PK/PD and toxicity profiles of ST-539 should allow further preclinical assessment of USP30 inhibition as a therapeutic strategy for a wide variety of diseases."

33890401

INDRA sources:

Colored badges next to statement headings correspond to evidence counts from knowledge sources, as shown below. Badges to the left of the | separator correspond to curated knowledge base sources, and badges to the right of it correspond to machine reading systems.

IndraLab

Statements

PK/PD inhibits USP30. 1 / 1

INDRA sources:

Databases

Reading